3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Urinary Bladder Neoplasms
12
Neoplasms
10
Carcinoma, Renal Cell
9
Ovarian Neoplasms
7
Carcinoma, Transitional Cell
7
Neoplasm Metastasis
6
Pancreatic Neoplasms
5
Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Carcinoma, Merkel Cell
4
Triple Negative Breast Neoplasms
3
Recurrence
3
Lymphoma
3
Lung Neoplasms
3
Fallopian Tube Neoplasms
3
Colorectal Neoplasms
3
Stomach Neoplasms
2
Prostatic Neoplasms
2
Melanoma
2
Leukemia, Myeloid, Acute
2
Kidney Neoplasms
2
Kidney Diseases
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Hepatocellular
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Turcot syndrome
1
Interventions
Rituximab
134
Cyclophosphamide
100
Vincristine
53
fludarabine phosphate
50
Prednisone
50
Doxorubicin
49
Etoposide
47
Peripheral Blood Stem Cell Transplantation
38
Mycophenolic Acid
37
Whole-Body Irradiation
35
Tacrolimus
29
Busulfan
27
Lenalidomide
26
Filgrastim
26
Cyclosporine
26
Melphalan
24
Methotrexate
21
Antilymphocyte Serum
21
Gemcitabine
18
ibritumomab tiuxetan
17
Granulocyte Colony-Stimulating Factor
17
Cytarabine
17
Carmustine
16
Radiotherapy
15
fludarabine
14
Carboplatin
14
Bendamustine Hydrochloride
14
pembrolizumab
13
ibrutinib
12
Sirolimus
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, Large B-Cell, Diffuse
×
avelumab
×
Clear all
NCT02951156
2020-12-17
Javelin DLBCL
Pfizer
Phase 3
Terminated
29 enrolled
24 charts